Patents by Inventor Xiao He

Xiao He has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20160333017
    Abstract: Substituted bicyclic heteroaryls and compositions containing them, for the treatment of general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, including but not restricted to autoimmune diseases such as systemic lupus erythematosis (SLE), myestenia gravis, rheumatoid arthritis, acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, multiples sclerosis, Sjoegren's syndrome and autoimmune hemolytic anemia, allergic conditions including all forms of hypersensitivity, The present invention also enables methods for treating cancers that are mediated, dependent on or associated with p110? activity, including but not restricted to leukemias, such as Acute Myeloid leukaemia (AML) Myelo-dysplastic syndrome (MDS) myelo-proliferative diseases (MPD) Chronic Myeloid Leukemia (CML) T-cell Acute Lympho
    Type: Application
    Filed: July 26, 2016
    Publication date: November 17, 2016
    Applicant: AMGEN INC.
    Inventors: Minna BUI, Yi CHEN, Timothy David CUSHING, Jason A. DUQUETTE, Benjamin FISHER, Felix GONZALEZ LOPEZ DE TURISO, Xiaolin HAO, Xiao HE, Michael G. JOHNSON, Brian LUCAS
  • Publication number: 20160301530
    Abstract: The present disclosure discloses a sensitive operation verification method, apparatus, and system, and belongs to the field of network security. The method includes: acquiring encrypted verification information on an operating terminal; decrypting the encrypted verification information according to decryption information corresponding to a user account to obtain verification information; receiving a result of verification that is performed on the sensitive operation by a user according to the verification information; encrypting the verification result according to encryption information corresponding to the user account to obtain an encrypted verification result; and providing the encrypted verification result to the operating terminal, so that the operating terminal feeds back the encrypted verification result to the server, and after the server detects that the encrypted verification result is that the verification succeeds, the server authorizes the operating terminal to execute the sensitive operation.
    Type: Application
    Filed: June 16, 2016
    Publication date: October 13, 2016
    Inventor: Xiao He
  • Publication number: 20160072795
    Abstract: Disclosed are a service locking method, apparatuses and systems thereof. The method includes: receiving a locking request including identification information of a designated service and an identifier of an operating terminal, the designated service being a service of performing a sensitive operation to network virtual property; and sending an authentication request containing the identification information of the designated service and the identifier of the operating terminal to an authentication server, and locking the designated service upon receiving successful authentication information from the authentication server.
    Type: Application
    Filed: November 19, 2015
    Publication date: March 10, 2016
    Applicant: TENCENT TECHNOLOGY (SHENZHEN) COMPANY LIMITED
    Inventors: Mingxue QIN, Xiao HE, Lei QIN, Yuye WANG
  • Publication number: 20150319173
    Abstract: A co-verification method, a two-dimensional code generation method, and a device and system therefor are provided. The method includes: performing first-type verification and second-type verification with a verification server, the first-type verification including at least one of user information verification, dynamic verification code verification, network shield verification, and token verification, and the second-type verification including two-dimensional verification; and receiving feedback information from the verification server, the feedback information being information sent by the verification server when the first-type verification and the second-type verification are both successful.
    Type: Application
    Filed: July 9, 2015
    Publication date: November 5, 2015
    Inventors: Shuai Hu, Xiao He
  • Publication number: 20150045361
    Abstract: Substituted bicyclic heteroaryls and compositions containing them, for the treatment of general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, including but not restricted to autoimmune diseases such as systemic lupus erythematosis (SLE), myestenia gravis, rheumatoid arthritis, acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, multiples sclerosis, Sjoegren's syndrome and autoimmune hemolytic anemia, allergic conditions including all forms of hypersensitivity, The present invention also enables methods for treating cancers that are mediated, dependent on or associated with p110? activity, including but not restricted to leukemias, such as Acute Myeloid leukaemia (AML) Myelo-dysplastic syndrome (MDS) myelo-proliferative diseases (MPD) Chronic Myeloid Leukemia (CML) T-cell Acute Lympho
    Type: Application
    Filed: October 22, 2014
    Publication date: February 12, 2015
    Inventors: Yi CHEN, Timothy D. CUSHING, Jason A. DUQUETTE, Felix GONZALEZ LOPEZ DE TURISO, Xiaolin HAO, Xiao HE, Brian S. LUCAS, Lawrence R. MCGEE, Andreas REICHELT, Robert M. RZASA, Jennifer L. SEGANISH, Youngsook SHIN, Dawei ZHANG
  • Patent number: 8901135
    Abstract: Substituted bicyclic heteroaryls having the following formula where the variables are as defined herein, and compositions containing them, for the treatment of general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, including but not restricted to autoimmune diseases such as systemic lupus erythematosis (SLE), myestenia gravis, rheumatoid arthritis, acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, multiples sclerosis, Sjoegren's syndrome and autoimmune hemolytic anemia, allergic conditions including all forms of hypersensitivity, The present invention also enables methods for treating cancers that are mediated, dependent on or associated with p110? activity, including but not restricted to leukemias, such as Acute Myeloid leukaemia (AML) Myelo-dysplastic syndrome (MDS) myelo-pro
    Type: Grant
    Filed: May 10, 2012
    Date of Patent: December 2, 2014
    Assignee: Amgen Inc.
    Inventors: Yi Chen, Timothy D. Cushing, Jason A. Duquette, Felix Gonzalez Lopez De Turiso, Xiaolin Hao, Xiao He, Brian Lucas, Lawrence R. McGee, Andreas Reichelt, Robert M. Rzasa, Jennifer Seganish, Youngsook Shin, Dawei Zhang
  • Publication number: 20140298254
    Abstract: A method for implementing a view mode switch of a graphical user interface (GUI) is provided. The method is performed at an electronic device with a touch screen display. In this method, a double-finger pinch gesture on a first sub-view object among a plurality of sub-view objects is detected, upon detection of the double-finger pinch gesture on the first sub-view object, the GUI performs a thumbnail-to-complete or complete-to-thumbnail view mode switch; an information content, which is associated with a sub-view object to be presented and adapted to the switched view mode of the GUI is acquired; and the sub-view object with the acquired information content is presented in the GUI.
    Type: Application
    Filed: April 24, 2014
    Publication date: October 2, 2014
    Inventors: Yu Peng, Tianzhe Dong, Xiao He, Yongsheng Zhao, Ziguang Gao, Heng Wang, Yelu Liu, Zhiming Zhao, Rui Guo
  • Publication number: 20140258919
    Abstract: A method for implementing a view mode switch of a graphical user interface (GUI) is disclosed. The method is performed at an electronic device with a touch screen display. In this method, a single-finger double-tap gesture on a first sub-view object among a plurality of sub-view objects is detected, upon detection of the single-finger double-tap gesture on the first sub-view object, the GUI performs a thumbnail-to-complete or complete-to-thumbnail view mode switch; an information content, which is associated with a sub-view object to be presented and adapted to the switched view mode of the GUI is acquired; and the sub-view object with the acquired information content is presented in the GUI.
    Type: Application
    Filed: April 28, 2014
    Publication date: September 11, 2014
    Inventors: Yu Peng, Tianzhe Dong, Xiao He, Yongsheng Zhao, Heng Wang, Yelu Liu, Zhiming Zhao, Rui Guo, Ziguang Gao
  • Patent number: 8765940
    Abstract: Substituted bicyclic heteroaryls and compositions containing them, for the treatment of general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, including but not restricted to autoimmune diseases such as systemic lupus erythematosis (SLE), myestenia gravis, rheumatoid arthritis, acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, multiples sclerosis, Sjoegren's syndrome and autoimmune hemolytic anemia, allergic conditions including all forms of hypersensitivity, The present invention also enables methods for treating cancers that are mediated, dependent on or associated with p110 activity, including but not restricted to leukemias, such as Acute Myeloid leukaemia (AML) Myelo-dysplastic syndrome (MDS) myelo-proliferative diseases (MPD) Chronic Myeloid Leukemia (CML) T-cell Acute Lymphob
    Type: Grant
    Filed: June 25, 2010
    Date of Patent: July 1, 2014
    Assignee: Amgen Inc.
    Inventors: Matthew Brown, Yi Chen, Timothy David Cushing, Felix Gonzalez Lopez De Turiso, Xiao He, Todd J. Kohn, Julia Winslow Lohman, Vatee Pattaropong, Jennifer Seganish, Youngsook Shin, Jillian L. Simard
  • Patent number: 8692789
    Abstract: A system and computer program product for establishing a wireless connection based on a touch screen of a wireless device. The wireless device includes a slide-out processing section for determining, in response to a slide-out from an edge of the touch screen, a first slide-out parameter for determining by the other wireless device an object to be connected, and broadcasting the first slide-out parameter. The wireless device further includes a slide-in processing section for determining a slide-in parameter in response to a slide-in from the edge of the touch screen and reception of a second slide-out parameter directionally transmitted from the other wireless device. Furthermore, if the determined slide-in parameter matches the second slide-out parameter, then the slide-in processing section establishes a wireless connection between the wireless device and the other wireless device. As a result, an authenticated wireless connection between short-range wireless terminals can be established more conveniently.
    Type: Grant
    Filed: October 19, 2011
    Date of Patent: April 8, 2014
    Assignee: International Business Machines Corporation
    Inventors: Yan Chen, Xiao He, Kuang Hu, Guo Jun Zhang
  • Patent number: 8658811
    Abstract: Described is a process for preparing docetaxel 1, including the following steps: a) hydroxyl acylation reaction of compound 2 and 3 to obtain compound 4; b) deprotection group R1 of the hydroxyl group of compound 4 obtained from step a to prepare compound 5; c) removing one tert-butoxycarbonyl of compound 5 obtained from step b to prepare compound 6; d) removing one acetyl of compound 6 obtained from step c to prepare compound 1; wherein, R1 represents tert-butyl dimethyl silyl, triethylsilyl, ethoxyethyl, tetrahydropyranyl, trichloroethoxycarbonyl or methoxymethyl, Boc is tert-butoxycarbonyl, Ac is acetyl, and Ph is phenyl. Also disclosed are intermediates of docetaxel and methods for preparation thereof.
    Type: Grant
    Filed: May 22, 2009
    Date of Patent: February 25, 2014
    Assignee: Shanghai Parling Pharma-Tech. Co., Ltd.
    Inventors: Xin Shen, Huaxing Zhan, Jidong Yang, Xiao He, Fuxing Lin, Shaohong Wu
  • Patent number: 8637576
    Abstract: Benzamide derivatives of formulae I and II, and pharmaceutically acceptable salts, solvates, stereoisomers, and prodrugs thereof, and pharmaceutical compositions comprising the same, are described and have therapeutic utility, particularly in the treatment of diabetes, obesity, and related conditions and disorders: wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, and R12 are defined as provided herein.
    Type: Grant
    Filed: October 20, 2009
    Date of Patent: January 28, 2014
    Assignee: Amgen Inc.
    Inventors: Jay P. Powers, Michael R. Degraffenreid, Xiao He, Lisa D. Julian, Dustin L. McMinn, Daqing Sun, Yosup Rew, Xuelei Yan
  • Patent number: 8609842
    Abstract: In the present invention, a synthesis method of Imatinib is disclosed, which comprises the following steps: the Imatinib, namely 4-(4-methyl-piperazin-1-ylmethyl)-N-[4-methyl-3-[4-(3-pyridinyl)-pyrimidin-2-ylamino]-benzami de shown in formula (III), is formed by reacting 4-methyl-N-3-(4-pyridin-3-yl-pyrimidin-2-yl)-1,3-benzenediamine shown in formula (I) with 4-(4-methyl-piperazin-1-methyl)-benzoic ester shown in formula (II), under the action of a base and in a non-protonic organic solvent, in the above generic chemical structural formula, R represents aliphatic alkyl having 1-10 carbon, phenyl, substituted phenyl, benzyl or substituted benzyl. The present invention provides a new synthesis method of Imatinib, which is formed under mild reaction conditions, and is environmentally friendly with a high-yield.
    Type: Grant
    Filed: April 23, 2010
    Date of Patent: December 17, 2013
    Assignees: Fujian South Pharmaceutical Co., Ltd., Shanghai Parling Pharmatech Co., Ltd.
    Inventors: Xin Shen, Xiao He, Jidong Yang, Shaohong Wu, Huaxing Zhan
  • Patent number: 8586739
    Abstract: Substituted bicyclic heteroaryls having the general structure: and compositions containing them, for the treatment of general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, including but not restricted to autoimmune diseases such as systemic lupus erythematosis (SLE), myestenia gravis, rheumatoid arthritis, acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, multiples sclerosis, Sjoegren's syndrome and autoimmune hemolytic anemia, allergic conditions including all forms of hypersensitivity.
    Type: Grant
    Filed: May 10, 2012
    Date of Patent: November 19, 2013
    Assignee: Amgen Inc.
    Inventors: Yi Chen, Timothy D. Cushing, Jason A. Duquette, Felix Gonzalez Lopez De Turiso, Xiaolin Hao, Xiao He, Brian S. Lucas, Lawrence R. McGee, Andreas Reichelt, Robert M. Rzasa, Jennifer L. Seganish, Youngsook Shin, Dawei Zhang
  • Patent number: 8575183
    Abstract: Substituted bicyclic heteroaryls and compositions containing them, for the treatment of general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, including but not restricted to autoimmune diseases such as systemic lupus erythematosis (SLE), myestenia gravis, rheumatoid arthritis, acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, multiples sclerosis, Sjoegren's syndrome and autoimmune hemolytic anemia, allergic conditions including all forms of hypersensitivity, The present invention also enables methods for treating cancers that are mediated, dependent on or associated with p110? activity, including but not restricted to leukemias, such as Acute Myeloid leukaemia (AML) Myelo-dysplastic syndrome (MDS) myelo-proliferative diseases (MPD) Chronic Myeloid Leukemia (CML) T-cell Acute Lympho
    Type: Grant
    Filed: April 1, 2011
    Date of Patent: November 5, 2013
    Assignee: Amgen Inc.
    Inventors: Timothy David Cushing, Jason A. Duquette, Xiao He, Julia Lohman, Youngsook Shin
  • Publication number: 20130041149
    Abstract: In the present invention, a synthesis method of Imatinib is disclosed, which comprises the following steps: the Imatinib, namely 4-(4-methyl-piperazin-1-ylmethyl)-N-[4-methyl-3-[4-(3-pyridinyl)-pyrimidin-2-ylamino]-benzamide shown in formula (III), is formed by reacting 4-methyl-N-3-(4-pyridin-3-yl-pyrimidin-2-yl)-1,3-benzenediamine shown in formula (I) with 4-(4-methyl-piperazin-1-methyl)-benzoic ester shown in formula (II), under the action of a base and in a non-protonic organic solvent, in the above generic chemical structural formula, R represents aliphatic alkyl having 1-10 carbon, phenyl, substituted phenyl, benzyl or substituted benzyl. The present invention provides a new synthesis method of Imatinib, which is formed under mild reaction conditions, and is environmentally friendly with a high-yield.
    Type: Application
    Filed: April 23, 2010
    Publication date: February 14, 2013
    Inventors: Xin Shen, Xiao He, Jidong Yang, Shaohong Wu, Huaxing Zhan
  • Patent number: 8329910
    Abstract: Substituted bicyclic heteroaryls and compositions containing them, for the treatment of general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, including but not restricted to autoimmune diseases such as systemic lupus erythematosis (SLE), myestenia gravis, rheumatoid arthritis, acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, multiples sclerosis, Sjoegren's syndrome and autoimmune hemolytic anemia, allergic conditions including all forms of hypersensitivity.
    Type: Grant
    Filed: July 20, 2011
    Date of Patent: December 11, 2012
    Assignee: Amgen Inc.
    Inventors: Yi Chen, Timothy D. Cushing, Xiaolin Hao, Xiao He, Andreas Reichelt, Robert M. Rzasa, Jennifer Seganish, Youngsook Shin, Dawei Zhang
  • Patent number: 8282430
    Abstract: An electrical contact includes a soldering plate, first curved plate extended upwardly from one end of the soldering plate, a middle plate extended from the free end of the curved plate, a second curved plate extended upwardly from the free end of the soldering plate, a contact plate extended from the free end of the second curved plate, a vertical plate extended downwardly from each of opposite lateral edges of the contact plate and beyond a bottom surface of the middle plate, and a restricting plate extended inwardly from the vertical plate and positioned between the soldering plate and the middle plate. The movement of the contact plate and the middle plate are limited to resist a vertical force for preventing the electrical contact from permanent deformation in a vertical direction by the restricting plates.
    Type: Grant
    Filed: February 3, 2010
    Date of Patent: October 9, 2012
    Assignee: Cheng Uei Precision Industry Co., Ltd.
    Inventors: Hang-Xiao He, Wei-Hong Liao, Ming-Chiang Chen
  • Publication number: 20120220586
    Abstract: Substituted bicyclic heteroaryls and compositions containing them, for the treatment of general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, including but not restricted to autoimmune diseases such as systemic lupus erythematosis (SLE), myestenia gravis, rheumatoid arthritis, acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, multiples sclerosis, Sjoegren's syndrome and autoimmune hemolytic anemia, allergic conditions including all forms of hypersensitivity, The present invention also enables methods for treating cancers that are mediated, dependent on or associated with p110? activity, including but not restricted to leukemias, such as Acute Myeloid leukaemia (AML) Myelo-dysplastic syndrome (MDS) myelo-proliferative diseases (MPD) Chronic Myeloid Leukemia (CML) T-cell Acute Lympho
    Type: Application
    Filed: May 10, 2012
    Publication date: August 30, 2012
    Applicant: Amgen Inc.
    Inventors: Yi Chen, Timothy D. Cushing, Jason A. Duquette, Felix Gonzalez Lopez De Turiso, Xiaolin Hao, Xiao He, Brian Lucas, Lawrence R. McGee, Andreas Reichelt, Robert M. Rzasa, Jennifer Seganish, Youngsook Shin, Dawei Zhang
  • Publication number: 20120220585
    Abstract: Substituted bicyclic heteroaryls and compositions containing them, for the treatment of general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, including but not restricted to autoimmune diseases such as systemic lupus erythematosis (SLE), myestenia gravis, rheumatoid arthritis, acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, multiples sclerosis, Sjoegren's syndrome and autoimmune hemolytic anemia, allergic conditions including all forms of hypersensitivity, The present invention also enables methods for treating cancers that are mediated, dependent on or associated with p110? activity, including but not restricted to leukemias, such as Acute Myeloid leukaemia (AML) Myelo-dysplastic syndrome (MDS) myelo-proliferative diseases (MPD) Chronic Myeloid Leukemia (CML) T-cell Acute Lympho
    Type: Application
    Filed: May 10, 2012
    Publication date: August 30, 2012
    Applicant: Amgen Inc.
    Inventors: Yi Chen, Timothy D. Cushing, Jason A. Duquette, Felix Gonzalez Lopez De Turiso, Xiaolin Hao, Xiao He, Brian Lucas, Lawrence R. McGee, Andreas Reichelt, Robert M. Rzasa, Jennifer Seganish, Youngsook Shin, Dawei Zhang